ERBB2 and neoplasm: Despite the fact that symptomatic standards has progressed in different bearings, one-third of a hundred thousand females pass on malignant growth of breast consistently [5], which is dependent on a number of variables, such as late diagnosis, the type of tumor, the number of lymph nodes involved at the time of tumor diagnosis, the size and grade of the tumor, the presence of the cellular marker for proliferation Ki67, the patient's age, the presence of the p53 mutation, and the presence of the human epidermal growth factor receptor 2 (HER2/neu) overexpression [6].